BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132-141. [PMID: 20578139 DOI: 10.1002/hep.23615] [Cited by in Crossref: 262] [Cited by in F6Publishing: 247] [Article Influence: 21.8] [Reference Citation Analysis]
Number Citing Articles
1 Moore MS, Ivanina E, Bornschlegel K, Qiao B, Schymura MJ, Laraque F. Hepatocellular Carcinoma and Viral Hepatitis in New York City. Clin Infect Dis 2016;63:1577-83. [PMID: 27585801 DOI: 10.1093/cid/ciw605] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
2 Zhao C, Jin M, Le RH, Le MH, Chen VL, Jin M, Wong GL, Wong VW, Lim YS, Chuang WL, Yu ML, Nguyen MH. Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. Liver Int. 2018;38:503-514. [PMID: 28834146 DOI: 10.1111/liv.13555] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
3 Strazzabosco M. Toward a rational management of very early hepatocellular carcinoma. Hepatology 2013;57:1300-2. [PMID: 22987787 DOI: 10.1002/hep.26074] [Reference Citation Analysis]
4 An JY, Peña MA, Cunha GM, Booker MT, Taouli B, Yokoo T, Sirlin CB, Fowler KJ. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics 2020;40:1916-31. [PMID: 33136476 DOI: 10.1148/rg.2020200104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
5 Okoronkwo N, Wang Y, Pitchumoni C, Koneru B, Pyrsopoulos N. Improved Outcomes Following Hepatocellular Carcinoma (HCC) Diagnosis in Patients Screened for HCC in a Large Academic Liver Center versus Patients Identified in the Community. J Clin Transl Hepatol 2017;5:31-4. [PMID: 28507924 DOI: 10.14218/JCTH.2016.00051] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Kim AK, Singal AG. Health disparities in diagnosis and treatment of hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2014;4:143-5. [PMID: 30992943 DOI: 10.1002/cld.427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
7 Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB (Oxford) 2011;13:783-91. [PMID: 21999591 DOI: 10.1111/j.1477-2574.2011.00355.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
8 Chinnaratha MA, Campbell K, Mathias R, McCormick RJ, Woodman RJ, Wigg AJ. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis. J Gastrointest Cancer 2019;50:888-93. [PMID: 30345486 DOI: 10.1007/s12029-018-0171-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Jo AJ, Choi WM, Kim HJ, Choi SH, Han S, Ko MJ, Lim YS. A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study. J Viral Hepat 2021. [PMID: 34762757 DOI: 10.1111/jvh.13631] [Reference Citation Analysis]
10 Tayob N, Corley DA, Christie I, Almers L, Rahal AK, Richardson P, White DL, Davila J, Kanwal F, El-Serag HB. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2020;. [PMID: 32768590 DOI: 10.1016/j.cgh.2020.07.065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Sutherland T, Watts J, Ryan M, Galvin A, Temple F, Vuong J, Little AF. Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening. J Med Imaging Radiat Oncol. 2017;61:34-39. [PMID: 27558976 DOI: 10.1111/1754-9485.12513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
12 Farvardin S, Patel J, Khambaty M, Yerokun OA, Mok H, Tiro JA, Yopp AC, Parikh ND, Marrero JA, Singal AG. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65:875-884. [PMID: 27531684 DOI: 10.1002/hep.28770] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 12.5] [Reference Citation Analysis]
13 Dai J, Zhao J, Du Y, Zhuang L, Ma Y, Chongsuvivatwong V. Clinico-Psychosocial Factors Predicting Hepatocellular Carcinoma Related Knowledge Among Patients with Chronic Liver Disease. J Cancer Educ 2020;35:937-45. [PMID: 31090039 DOI: 10.1007/s13187-019-01545-y] [Reference Citation Analysis]
14 Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S34-43. [PMID: 21739567 DOI: 10.1002/lt.22369] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
15 Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2174-2181. [PMID: 28474143 DOI: 10.1007/s10620-017-4595-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
16 Massoud O, Charlton M. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clinics in Liver Disease 2018;22:201-11. [DOI: 10.1016/j.cld.2017.08.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
17 Choi DT, Davila JA, Sansgiry S, David E, Singh H, El-Serag HB, Hsiao-Fan Sada Y. Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1679-87. [PMID: 32693047 DOI: 10.1016/j.cgh.2020.07.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Hesketh RL, Zhu AX, Oklu R. Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol 2015;21:78-84. [PMID: 25430530 DOI: 10.5152/dir.2014.14237] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
19 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
20 Piñero F, Rubinstein F, Marciano S, Fernández N, Silva J, Zambelo Y, Anders M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?Dig Dis Sci. 2019;64:718-728. [PMID: 30511199 DOI: 10.1007/s10620-018-5390-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 de la Torre A, Ahmad M, Ayoub F, Korogodsky M, Pichardo N, Green L, Montesdeoca A, Mcdowall P, Danko C. Electronic health record year and country of birth testing and patient navigation to increase diagnosis of chronic viral hepatitis. J Viral Hepat 2019;26:911-8. [DOI: 10.1111/jvh.13098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
22 Xu K, Watanabe-Galloway S, Rochling FA, Zhang J, Farazi PA, Peng H, Wang H, Luo J. Practice, Knowledge, and Barriers for Screening of Hepatocellular Carcinoma Among High-Risk Chinese Patients. Ann Glob Health 2017;83:281-92. [PMID: 28619403 DOI: 10.1016/j.aogh.2017.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
23 Khan FZ, Perumpail RB, Wong RJ, Ahmed A. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol 2015; 7(18): 2155-2161 [PMID: 26328027 DOI: 10.4254/wjh.v7.i18.2155] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
24 Jan T, Medvedev S, Cannon RM, Saggi B, Mcgee J, Paramesh A, Killackey M, Shores NJ, Slakey DP, Balart L, Buell JF. Racial disparity and their impact on hepatocellular cancer outcomes in inner-city New Orleans. Surgery 2012;152:661-7. [DOI: 10.1016/j.surg.2012.07.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
25 Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaifi JT, Staveley-O’Carroll K. Impact of genetic targets on cancer therapy: hepatocellular cancer. Adv Exp Med Biol. 2013;779:67-90. [PMID: 23288636 DOI: 10.1007/978-1-4614-6176-0_4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
26 Borzio M, Fornari F, De Sio I, Andriulli A, Terracciano F, Parisi G, Francica G, Salvagnini M, Marignani M, Salmi A, Farinati F, Carella A, Pedicino C, Dionigi E, Fanigliulo L, Cazzaniga M, Ginanni B, Sacco R; EpaHCC Group. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncol 2013;9:283-94. [PMID: 23414477 DOI: 10.2217/fon.12.183] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
27 Rich NE, Parikh ND, Singal AG. Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. Semin Liver Dis 2017;37:296-304. [PMID: 29272892 DOI: 10.1055/s-0037-1608775] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
28 Mohsen W, Levy MT. Hepatitis A to E: what's new? Intern Med J 2017;47:380-9. [PMID: 28401719 DOI: 10.1111/imj.13386] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
29 Otete H, Deleuran T, Fleming KM, Card T, Aithal GP, Jepsen P, West J. Hip fracture risk in patients with alcoholic cirrhosis: A population-based study using English and Danish data. Journal of Hepatology 2018;69:697-704. [DOI: 10.1016/j.jhep.2018.04.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
30 Rodríguez de Lope C, Reig M, Matilla A, Ferrer MT, Dueñas E, Mínguez B, F Castroagudín J, Ortiz I, Pascual S, Lledó JL, Gallego A, Arenas JI, Aracil C, Forne M, Muñoz C, Pons F, Sala M, Iñarrairaegui M, Martin-Llahi M, Andreu V, Garre C, Rendón P, Fuentes J, Crespo J, Rodríguez M, Bruix J, Varela M; en representación del Grupo de Estudio de Cáncer Hepático (GECH). Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. Med Clin (Barc) 2017;149:61-71. [PMID: 28279536 DOI: 10.1016/j.medcli.2016.12.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
31 Dhanasekaran R, Talwalkar JA. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep 2015;17:34. [PMID: 26238927 DOI: 10.1007/s11894-015-0459-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Sinn DH, Kang D, Kang M, Paik SW, Guallar E, Cho J, Gwak GY. Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. BMC Cancer 2019;19:286. [PMID: 30922251 DOI: 10.1186/s12885-019-5508-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Huang DQ, Hoang JK, Leong J, Riveiro-Barciela M, Maeda M, Yang JD, Accarino EV, Thin K, Trinh L, Cheung RC, Roberts LR, Buti M, Schwartz M, Nguyen MH. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 2021;41:1922-32. [PMID: 33713386 DOI: 10.1111/liv.14877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Shoreibah MG, Bloomer JR, McGuire BM, Massoud OI. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am J Med Sci. 2014;347:415-419. [PMID: 24759379 DOI: 10.1097/maj.0000000000000200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
35 El-Serag HB. Surveillance for hepatocellular carcinoma: long way to achieve effectiveness. Dig Dis Sci. 2012;57:3050-3051. [PMID: 23053890 DOI: 10.1007/s10620-012-2413-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
36 Tran SA, Le A, Zhao C, Hoang J, Yasukawa LA, Weber S, Henry L, Nguyen MH. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol 2018;5:e000192. [PMID: 29607053 DOI: 10.1136/bmjgast-2017-000192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
37 Shariff MI, Kim JU, Ladep NG, Crossey MM, Koomson LK, Zabron A, Reeves H, Cramp M, Ryder S, Greer S, Cox IJ, Williams R, Holmes E, Nash K, Taylor-Robinson SD. Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. J Clin Exp Hepatol 2016;6:186-94. [PMID: 27746614 DOI: 10.1016/j.jceh.2016.03.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
38 Ohikere K, Chitnis AS, Hahambis TA, Singal A, Wong RJ. Ethnic Minorities and Low Socioeconomic Status Patients With Chronic Liver Disease Are at Greatest Risk of Being Uninsured. Gastroenterology Res 2021;14:313-23. [PMID: 35059065 DOI: 10.14740/gr1439] [Reference Citation Analysis]
39 Wang X, Wang N, Cheung F, Lao L, Li C, Feng Y. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms. J Integr Med. 2015;13:142-164. [PMID: 26006028 DOI: 10.1016/s2095-4964(15)60171-6] [Cited by in Crossref: 61] [Cited by in F6Publishing: 42] [Article Influence: 8.7] [Reference Citation Analysis]
40 Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
41 Eskesen AN, Bjøro K, Aandahl EM, Line PD, Melum E. Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway--a population-based cohort study. Cancer Epidemiol. 2014;38:741-747. [PMID: 25454262 DOI: 10.1016/j.canep.2014.10.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
42 Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, Richardson P, Davila JA, Kanwal F. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther 2016;43:621-30. [PMID: 26784271 DOI: 10.1111/apt.13505] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
43 Singal AG, Ioannou GN. For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective? Clin Gastroenterol Hepatol 2019;17:1732-5. [PMID: 30772587 DOI: 10.1016/j.cgh.2019.02.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
44 Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLoS One 2020;15:e0240542. [PMID: 33052942 DOI: 10.1371/journal.pone.0240542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
45 West J, Card TR, Aithal GP, Fleming KM. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment Pharmacol Ther 2017;45:983-90. [DOI: 10.1111/apt.13961] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
46 Yan M, Ha J, Aguilar M, Liu B, Frenette CT, Bhuket T, Wong RJ. Older Patients With Hepatocellular Carcinoma Have More Advanced Disease, Lower Rates of Treatment, and Lower Survival. Journal of Clinical Gastroenterology 2017;51:378-83. [DOI: 10.1097/mcg.0000000000000590] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
47 Goldberg DS, Valderrama A, Kamalakar R, Sansgiry SS, Babajanyan S, Lewis JD. Hepatocellular carcinoma surveillance rates in commercially insured patients with noncirrhotic chronic hepatitis B. J Viral Hepat 2015;22:727-36. [PMID: 25581816 DOI: 10.1111/jvh.12381] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
48 Choi MH, Jung SE, Choi JI, Jeong WK, Kim HC, Kim Y, Kim Y, Park B. Quality Management of Ultrasound Surveillance for Hepatocellular Carcinoma Under the Korean National Cancer Screening Program. J Ultrasound Med 2018;37:245-54. [PMID: 28736862 DOI: 10.1002/jum.14339] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:1927-33.e2. [PMID: 24582947 DOI: 10.1016/j.cgh.2014.02.025] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 8.0] [Reference Citation Analysis]
50 Patel N, Yopp AC, Singal AG. Diagnostic delays are common among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2015;13:543-9. [PMID: 25964640 DOI: 10.6004/jnccn.2015.0074] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
51 Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Clin Mol Hepatol. 2019;25:264-269. [PMID: 30827081 DOI: 10.3350/cmh.2019.1001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
52 Sanoff HK, Chang Y, Reimers M, Lund JL. Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries With Hepatocellular Carcinoma. J Oncol Pract 2017;13:e197-206. [PMID: 28029300 DOI: 10.1200/JOP.2016.017814] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
53 Sheppard-Law S, Zablotska-Manos I, Kermeen M, Holdaway S, Lee A, George J, Zekry A, Maher L. Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy. J Clin Nurs 2018;27:2673-83. [PMID: 29603817 DOI: 10.1111/jocn.14367] [Reference Citation Analysis]
54 Davila JA, Kramer JR, Duan Z, Richardson PA, Tyson GL, Sada YH, Kanwal F, El-Serag HB. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858-1868. [PMID: 23359313 DOI: 10.1002/hep.26287] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
55 Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19:23-43. [PMID: 25454295 DOI: 10.1016/j.cld.2014.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
56 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Cisneros-garza L, González-huezo M, López-cossio J, Kuljacha-gastelum A. Caracterización del carcinoma hepatocelular en México. Revista de Gastroenterología de México 2018;83:223-7. [DOI: 10.1016/j.rgmx.2017.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Yang JD, Kim WR. Surveillance for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:16-21. [PMID: 21699816 DOI: 10.1016/j.cgh.2011.06.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
59 Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11:472-477. [PMID: 23200983 DOI: 10.1016/j.cgh.2012.11.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
60 Kuo SC, Lin CN, Lin YJ, Chen WY, Hwang JS, Wang JD. Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan. JAMA Netw Open 2021;4:e2114680. [PMID: 34165580 DOI: 10.1001/jamanetworkopen.2021.14680] [Reference Citation Analysis]
61 Schütte K, Bornschein J, Kahl S, Seidensticker R, Arend J, Ricke J, Malfertheiner P. Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver Cancer 2012;1:257-66. [PMID: 24159590 DOI: 10.1159/000343840] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
62 Jiar N, Slama JL, Ganne-Carrié N. [Screening of hepatocellular carcinoma in patients with uncomplicated cirrhosis in real life: Practices survey of general practionners from three towns of Seine-Saint-Denis (north-east suburb of Paris)]. Bull Cancer 2017;104:618-24. [PMID: 28688744 DOI: 10.1016/j.bulcan.2017.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci 2014;59:3073-7. [PMID: 25027206 DOI: 10.1007/s10620-014-3256-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
64 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
65 Kim AK, Hamilton JP, Lin SY, Chang T, Hann H, Hu C, Lou Y, Lin Y, Gade TP, Park G, Luu H, Lee T, Wang J, Chen D, Goggins MG, Jain S, Song W, Su Y. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. [DOI: 10.1038/s41416-022-01706-9] [Reference Citation Analysis]
66 Perumalswami PV, Wyatt B, Bowman CA, Patel K, Mageras A, Lewis SC, Branch AD. Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C. Cancer Med 2022. [PMID: 35261196 DOI: 10.1002/cam4.4508] [Reference Citation Analysis]
67 Singal AG, Mittal S, Yerokun OA, Ahn C, Marrero JA, Yopp AC, Parikh ND, Scaglione SJ. Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. Am J Med. 2017;130:1099-1106.e1. [PMID: 28213044 DOI: 10.1016/j.amjmed.2017.01.021] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 10.4] [Reference Citation Analysis]
68 Beste LA, Ioannou GN, Yang Y, Chang MF, Ross D, Dominitz JA. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol 2015;13:172-9. [PMID: 24813175 DOI: 10.1016/j.cgh.2014.04.033] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
69 Cisneros-garza L, González-huezo M, López-cossio J, Kuljacha-gastelum A. Characterization of hepatocellular carcinoma in Mexico. Revista de Gastroenterología de México (English Edition) 2018;83:223-7. [DOI: 10.1016/j.rgmxen.2017.06.005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, McGlynn KA, Greten TF, Altekruse SF. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology. 2014;60:1637-1644. [PMID: 24996116 DOI: 10.1002/hep.27288] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
71 Shaltiel T, Zheng S, Siderides C, Gleeson EM, Carr J, Pletcher ER, Cohen NA, Golas BJ, Magge DR, Labow DM, Branch AD, Sarpel U. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer 2021;127:1395-406. [PMID: 33629759 DOI: 10.1002/cncr.33377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Hirata A, Hirata T, Takahashi Y, Nakayama T. Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database. Hepatol Res. 2017;47:283-292. [PMID: 27027417 DOI: 10.1111/hepr.12714] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
73 Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis. 2013;17:375-397. [PMID: 23905811 DOI: 10.1016/j.cld.2013.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
74 Goebel M, Singal AG, Nodora J, Castañeda SF, Martinez E, Doubeni C, Laiyemo A, Gupta S. How can we boost colorectal and hepatocellular cancer screening among underserved populations? Curr Gastroenterol Rep 2015;17:22. [PMID: 26031831 DOI: 10.1007/s11894-015-0445-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
75 Khalil A, Elsheashaey A, Abdelsameea E, Obada M, Mohamed Bayomy FF, El-said H. Role of bile acids in the prediction of hepatocellular carcinoma in HCV-induced liver cirrhosis. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00142-3] [Reference Citation Analysis]
76 Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123:542-551. [PMID: 21800047 DOI: 10.1007/s00508-011-0033-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
77 Chen Q, Ayer T, Adee MG, Wang X, Kanwal F, Chhatwal J. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Netw Open. 2020;3:e2021173. [PMID: 33206188 DOI: 10.1001/jamanetworkopen.2020.21173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Li R, Yuan MX, Ma KS, Li XW, Tang CL, Zhang XH, Guo DY, Yan XC. Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One. 2014;9:e98612. [PMID: 24874413 DOI: 10.1371/journal.pone.0098612] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
79 Jasirwan COM, Hasan I, Sulaiman AS, Lesmana CRA, Kurniawan J, Kalista KF, Nababan SH, Gani RA. Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia. Curr Probl Cancer 2020;44:100480. [PMID: 31130257 DOI: 10.1016/j.currproblcancer.2019.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
80 Borzio M, Dionigi E, Vitale A, Rossini A, Marignani M, Fornari F, Vicari S, De Sio I, Farinati F, Bertolini E, Oliveri F, Leandro G, Francica G, Mitra M, Omazzi B, Boccia S, Salmi A, Toldi A, Sacco R. Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. Liver Int 2017;37:1184-92. [DOI: 10.1111/liv.13392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
81 Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Virdone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA. LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. Am J Gastroenterol. 2016;111:70-77. [PMID: 26729544 DOI: 10.1038/ajg.2015.389] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
82 Yang JD, Dai J, Singal AG, Gopal P, Addissie BD, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Gores GJ, Feng Z, Marrero JA, Roberts LR. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. Cancer Epidemiol Biomarkers Prev 2017;26:1085-92. [PMID: 28258053 DOI: 10.1158/1055-9965.EPI-16-0747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
83 Trinchet JC. Surveillance for hepatocellular carcinoma in cirrhotic patients: from official recommendations to the real life. J Hepatol 2011;54:1310-1. [PMID: 21296113 DOI: 10.1016/j.jhep.2010.11.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
84 Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer. 2012;1:94-109. [PMID: 24159577 DOI: 10.1159/000342404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
85 Majerović M, Jelaković M, Premužić M, Štromar IK, Radić D, Mance M, Pleština S, Ostojić R, Rustemović N, Krznarić Z. Hepatocellular Carcinoma Surveillance-Experience from Croatian Referral Centre for Chronic Liver Diseases. J Gastrointest Cancer 2019;50:48-53. [PMID: 29127665 DOI: 10.1007/s12029-017-0011-1] [Reference Citation Analysis]
86 Scaglione S, Adams W, Caines A, Devlin P, Mittal S, Singal AG, Parikh ND. Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma. Dig Dis Sci. 2020;65:1669-1678. [PMID: 31643036 DOI: 10.1007/s10620-019-05890-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
87 Hoshida Y. Molecular Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2012;1:177-9. [PMID: 26213618 DOI: 10.1002/cld.117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
88 Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013;38:343-64. [DOI: 10.1111/apt.12381] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
89 Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13:791-8.e1. [PMID: 25019694 DOI: 10.1016/j.cgh.2014.06.031] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 7.5] [Reference Citation Analysis]
90 Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology 2014;59:1471-81. [PMID: 24677195 DOI: 10.1002/hep.26944] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
91 Chon YE, Jung KS, Kim MJ, Choi JY, An C, Park JY, Ahn SH, Kim BK, Kim SU, Park H, Hwang SK, Rim KS, Han KH, Kim DY. Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Aliment Pharmacol Ther 2018;47:1201-12. [PMID: 29492988 DOI: 10.1111/apt.14578] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
92 Seshadri RM, Besur S, Niemeyer DJ, Templin M, McKillop IH, Swan RZ, Martinie JB, Russo MW, Iannitti DA. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) 2014;16:1102-9. [PMID: 24964271 DOI: 10.1111/hpb.12300] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
93 McGowan CE, Edwards TP, Luong MU, Hayashi PH. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol 2015;13:799-804. [PMID: 25117773 DOI: 10.1016/j.cgh.2014.07.056] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
94 Gaba RC, Kallwitz ER, Parvinian A, Bui JT, Roenn NMV, Berkes JL, Cotler SJ. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. Annals of Hepatology 2013;12:766-73. [DOI: 10.1016/s1665-2681(19)31318-3] [Cited by in Crossref: 21] [Article Influence: 2.3] [Reference Citation Analysis]
95 Selvapatt N, House H, Brown A. Hepatocellular Carcinoma Surveillance: Are We Utilizing It? J Clin Gastroenterol 2016;50:e8-e12. [PMID: 26018132 DOI: 10.1097/MCG.0000000000000344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
96 Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology 2018;155:431-442.e10. [PMID: 29729258 DOI: 10.1053/j.gastro.2018.04.027] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
97 Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol 2015;13:219-34. [PMID: 25791207 DOI: 10.1007/s11938-015-0049-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
98 Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. Hepatology 2021;73:713-25. [PMID: 32383272 DOI: 10.1002/hep.31309] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
99 Hassett M, Yopp AC, Singal AG, Palmer BF. Surveillance for Hepatocellular Carcinoma: How Can We Do Better? The American Journal of the Medical Sciences 2013;346:308-13. [DOI: 10.1097/maj.0b013e31828318ff] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
100 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
101 Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013;144:1024-30. [PMID: 23333348 DOI: 10.1053/j.gastro.2013.01.021] [Cited by in Crossref: 125] [Cited by in F6Publishing: 121] [Article Influence: 13.9] [Reference Citation Analysis]
102 Hernaez R, El-serag HB. Hepatocellular carcinoma surveillance: The road ahead: Hernaez and El-serag. Hepatology 2017;65:771-3. [DOI: 10.1002/hep.28983] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
103 Jin C, Zhang XY, Li JW, Li C, Peng W, Wen TF, Luo Y, Lu Q, Zhong XF, Zhang JY, Yan LN, Yang JY. Impact of tumor size and cirrhotic background for differentiating HCC and ICC with CEUS: does it matter for patients undergoing hepatectomy? Oncotarget 2017;8:83698-711. [PMID: 29137375 DOI: 10.18632/oncotarget.19624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
104 Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, Pedrosa I, Khatri G, Yakoo T, Meyer JJ. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014;21:1287-1295. [PMID: 24318095 DOI: 10.1245/s10434-013-3413-8] [Cited by in Crossref: 102] [Cited by in F6Publishing: 82] [Article Influence: 11.3] [Reference Citation Analysis]
105 Webb GJ, Wright KV, Harrod EC, Gorard DA, Collier JD, Evans AK. Surveillance for hepatocellular carcinoma in a mixed-aetiology UK cohort with cirrhosis: does α-fetoprotein still have a role? Clin Med (Lond) 2015;15:139-44. [PMID: 25824065 DOI: 10.7861/clinmedicine.15-2-139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
106 Cucchetti A, Cescon M, Erroi V, Pinna AD. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol. 2013;27:961-972. [PMID: 24182614 DOI: 10.1016/j.bpg.2013.08.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
107 Hung Y, Lin C, Liu C, Hung H, Lin S, Lee S, Chen P, Chuang S, Yu M. Development of risk scoring system for stratifying population for hepatocellular carcinoma screening: HUNG ET AL. Hepatology 2015;61:1934-44. [DOI: 10.1002/hep.27610] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
108 Singal AG, Li X, Tiro J, Kandunoori P, Adams-Huet B, Nehra MS, Yopp A. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015;128:90.e1-90.e7. [PMID: 25116425 DOI: 10.1016/j.amjmed.2014.07.027] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 9.3] [Reference Citation Analysis]
109 Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma: A standard of care, not a clinical option. Hepatology 2011;54:1898-900. [DOI: 10.1002/hep.24684] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
110 Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, Orsini L, Kim WR, Roberts LR. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011;9:617-623.e1. [PMID: 21459158 DOI: 10.1016/j.cgh.2011.03.027] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 7.1] [Reference Citation Analysis]
111 El-Shamy A, Eng FJ, Doyle EH, Klepper AL, Sun X, Sangiovanni A, Iavarone M, Colombo M, Schwartz RE, Hoshida Y, Branch AD. A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. J Hepatol 2015;63:1323-33. [PMID: 26220749 DOI: 10.1016/j.jhep.2015.07.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
112 Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol 2020;7:HEP25. [PMID: 32774835 DOI: 10.2217/hep-2020-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: A systematic review. J Gen Intern Med. 2012;27:861-867. [PMID: 22215266 DOI: 10.1007/s11606-011-1952-x] [Cited by in Crossref: 166] [Cited by in F6Publishing: 154] [Article Influence: 16.6] [Reference Citation Analysis]
114 Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol 2017;8:e101. [PMID: 28640287 DOI: 10.1038/ctg.2017.26] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 12.8] [Reference Citation Analysis]
115 Kheraj R, Tewani SK, Ketwaroo G, Leffler DA. Quality improvement in gastroenterology clinical practice. Clin Gastroenterol Hepatol. 2012;10:1305-1314. [PMID: 22902758 DOI: 10.1016/j.cgh.2012.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
116 Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS, Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites: The benefit of paracentesis. Journal of Gastroenterology and Hepatology 2016;31:1025-30. [DOI: 10.1111/jgh.13255] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
117 Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015;61:184-90. [DOI: 10.1002/hep.27443] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 10.9] [Reference Citation Analysis]
118 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624. [PMID: 24691105 DOI: 10.1371/journal.pmed.1001624] [Cited by in Crossref: 364] [Cited by in F6Publishing: 339] [Article Influence: 45.5] [Reference Citation Analysis]
119 Wong RJ, Ahmed A; Hepatocellular Carcinoma Research Committee of the Chronic Liver Disease Foundation. Understanding Gaps in the Hepatocellular Carcinoma Cascade of Care: Opportunities to Improve Hepatocellular Carcinoma Outcomes.J Clin Gastroenterol. 2020;54:850-856. [PMID: 33030855 DOI: 10.1097/MCG.0000000000001422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-292. [PMID: 23507917 DOI: 10.1097/mog.0b013e32835ff1cf] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
121 Borzio M, Sacco R. Nonadherence to guidelines in the management of hepatocellular carcinoma: an Italian or universal phenomenon? Future Oncol. 2013;9:465-467. [PMID: 23560367 DOI: 10.2217/fon.13.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
122 Jou JH, Muir AJ. Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol 2018;16:19-20. [PMID: 28694129 DOI: 10.1016/j.cgh.2017.06.049] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
123 Burman B, Helton WS. Disparities in care for patients with curable hepatocellular carcinoma. HPB (Oxford) 2015;17:745-6. [PMID: 26278320 DOI: 10.1111/hpb.12477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y; Precision Liver Cancer Prevention Consortium. Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell 2016;30:879-90. [PMID: 27960085 DOI: 10.1016/j.ccell.2016.11.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 100] [Article Influence: 20.2] [Reference Citation Analysis]
125 Kennedy NA, Rodgers A, Altus R, McCormick R, Wundke R, Wigg AJ. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Intern Med J 2013;43:772-7. [PMID: 23611607 DOI: 10.1111/imj.12166] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
126 Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. Liver Transpl 2019;25:369-79. [PMID: 30582779 DOI: 10.1002/lt.25398] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
127 Wong LL, Ogihara M, Ji J, Tsai N. The changing characteristics of hepatocellular cancer in Hawaii over time. Am J Surg 2015;210:146-52. [PMID: 25510478 DOI: 10.1016/j.amjsurg.2014.06.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
128 Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:1886-1893.e5. [PMID: 30557738 DOI: 10.1016/j.cgh.2018.12.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
129 Abara WE, Spradling P, Zhong Y, Moorman A, Teshale EH, Rupp L, Gordon SC, Schmidt M, Boscarino JA, Daida YG, Holmberg SD; CHeCS Investigators. Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis. J Gastrointest Cancer 2020;51:461-8. [PMID: 31124041 DOI: 10.1007/s12029-019-00255-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:105-114. [PMID: 26157746 DOI: 10.3350/cmh.2015.21.2.105] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 11.4] [Reference Citation Analysis]
131 El-Shamy A, Pendleton M, Eng FJ, Doyle EH, Bashir A, Branch AD. Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients. Sci Rep. 2016;6:27025. [PMID: 27246310 DOI: 10.1038/srep27025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
132 Hsiao P, Hsieh KC, Chen YS, Hsu CC, Lo GH, Li YC, Hsieh PM, Lin HY, Wu TC, Yeh JH, Lin CW. Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e16074. [PMID: 31232945 DOI: 10.1097/MD.0000000000016074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
133 Singal AG, Tiro J, Li X, Adams-Huet B, Chubak J. Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. J Clin Gastroenterol 2017;51:650-5. [PMID: 27870642 DOI: 10.1097/MCG.0000000000000708] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
134 Chaiteerakij R, Chattieng P, Choi J, Pinchareon N, Thanapirom K, Geratikornsupuk N. Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted Analysis. Annals of Hepatology 2017;16:421-9. [DOI: 10.5604/01.3001.0009.8597] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
135 Hoffmann AC, Gerken GG. Hepatocellular Cancer: New Kids on the Block. Gastrointest Tumors 2014;1:195-200. [PMID: 26676221 DOI: 10.1159/000380787] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
136 Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world? Clin Mol Hepatol 2017;23:239-48. [PMID: 28706177 DOI: 10.3350/cmh.2017.0008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
137 Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016;36:166-76. [PMID: 26386254 DOI: 10.1111/liv.12965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
138 González Huezo MS, Sánchez Ávila JF. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Revista de Gastroenterología de México 2014;79:250-62. [DOI: 10.1016/j.rgmx.2014.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
139 Estevez J, Yang JD, Leong J, Nguyen P, Giama NH, Zhang N, Ali HA, Lee M, Cheung R, Roberts L, Schwartz M, Nguyen MH. Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. Am J Gastroenterol 2019;114:80-8. [DOI: 10.1038/s41395-018-0261-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
140 Ladhani S, Ohri A, Wong RJ. Disparities in Hepatocellular Carcinoma Surveillance: Dissecting the Roles of Patient, Provider, and Health System Factors. Journal of Clinical Gastroenterology 2020;54:218-26. [DOI: 10.1097/mcg.0000000000001313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
141 Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M, Lee WM, Marrero JA, Tiro JA. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:1124-30. [PMID: 22846843 DOI: 10.1158/1940-6207.CAPR-12-0046] [Cited by in Crossref: 120] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
142 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
143 Aberra FB, Essenmacher M, Fisher N, Volk ML. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013;58:1157-1160. [PMID: 23111632 DOI: 10.1007/s10620-012-2461-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
144 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
145 Costentin C. [Hepatocellular carcinoma surveillance]. Presse Med 2017;46:381-5. [PMID: 28081946 DOI: 10.1016/j.lpm.2016.11.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
146 Goldberg DS, Lewis JD, Halpern SD, Weiner MG, Lo Re V 3rd. Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. Pharmacoepidemiol Drug Saf 2013;22:103-7. [PMID: 23124932 DOI: 10.1002/pds.3367] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
147 Rajbhandari R, Simon RE, Chung RT, Ananthakrishnan AN. Racial Disparities in Inhospital Outcomes for Hepatocellular Carcinoma in the United States. Mayo Clin Proc 2016;91:1173-82. [PMID: 27497857 DOI: 10.1016/j.mayocp.2016.06.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
148 Meer SV, Man RA, Siersema PD, Erpecum KJV. Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol 2013; 19(40): 6744-6756 [PMID: 24187450 DOI: 10.3748/wjg.v19.i40.6744] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
149 Choi DT, Kum HC, Park S, Ohsfeldt RL, Shen Y, Parikh ND, Singal AG. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2019;17:976-987.e4. [PMID: 30616961 DOI: 10.1016/j.cgh.2018.10.031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
150 Kangas-Dick A, Gall V, Hilden P, Turner A, Greenbaum A, Sesti J, Paul S, Carpizo D, Kennedy T, Sadaria Grandhi M, Alexander HR, Wang S, Geffner S, August D, Langan RC. Disparities in utilization of services for racial and ethnic minorities with hepatocellular carcinoma associated with hepatitis C. Surgery 2020;168:49-55. [PMID: 32414566 DOI: 10.1016/j.surg.2020.03.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Nakagawa S, Yamashita YI, Umezaki N, Yamao T, Kaida T, Hiyoshi Y, Mima K, Okabe H, Hayashi H, Imai K, Chikamoto A, Baba H. Four gene intrahepatic metastasis-risk signature predicts hepatocellular carcinoma malignant potential and early recurrence from intrahepatic metastasis. Surgery 2021;169:903-10. [PMID: 33160638 DOI: 10.1016/j.surg.2020.09.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Harris N, Gorelik A, Gibson RN. Targeted ultrasound of the liver: Impact on scanning time of a new approach in chronic liver disease. J Med Imaging Radiat Oncol 2017;61:448-52. [DOI: 10.1111/1754-9485.12595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
153 Panda D. Role of surveillance in prevention of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S43-9. [PMID: 25755610 DOI: 10.1016/j.jceh.2014.03.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
154 Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, Murphy C, McCallister K, Singal AG. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017;65:1196-1205. [PMID: 27775821 DOI: 10.1002/hep.28895] [Cited by in Crossref: 97] [Cited by in F6Publishing: 96] [Article Influence: 16.2] [Reference Citation Analysis]
155 Li DJ, Park Y, Vachharajani N, Aung WY, Garonzik-Wang J, Chapman WC. Physician-Patient Communication is Associated With Hepatocellular Carcinoma Screening in Chronic Liver Disease Patients. J Clin Gastroenterol 2017;51:454-60. [PMID: 27918312 DOI: 10.1097/MCG.0000000000000747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
156 Huang Y, Wallace MC, Adams LA, MacQuillan G, Garas G, Ferguson J, Samuelson S, Tibballs J, Jeffrey GP. Rate of Nonsurveillance and Advanced Hepatocellular Carcinoma at Diagnosis in Chronic Liver Disease. J Clin Gastroenterol 2018;52:551-6. [PMID: 28858944 DOI: 10.1097/MCG.0000000000000916] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
157 Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384-398. [PMID: 22846857 DOI: 10.1053/j.seminoncol.2012.05.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
158 Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 2019;70:284-93. [PMID: 30658729 DOI: 10.1016/j.jhep.2018.10.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 32.0] [Reference Citation Analysis]
159 Tian C, Singal AG. Clinical reminders for hepatocellular carcinoma surveillance: an early step in a long journey. Clin Gastroenterol Hepatol 2015;13:180-2. [PMID: 25086194 DOI: 10.1016/j.cgh.2014.07.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Bou About G, Thiebault E, Wattenhofer-Donzé M, Jacobs H, Guimond A, Sorg T, Robinet E, Baumert TF, Monassier L, Herault Y. Ultrasound-Guided Approaches to Improve Orthotopic Mouse Xenograft Models for Hepatocellular Carcinoma. Curr Protoc Mouse Biol 2019;9:e62. [PMID: 31145554 DOI: 10.1002/cpmo.62] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
161 Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surg Nutr 2016;5:43-52. [PMID: 26904556 DOI: 10.3978/j.issn.2304-3881.2015.08.05] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
162 Nomoto S, Hishida M, Inokawa Y, Takano N, Kanda M, Nishikawa Y, Fujii T, Koike M, Sugimoto H, Kodera Y. Expression analysis of THOP1 in background liver, a prognostic predictive factor in hepatocellular carcinoma, extracted by multiarray analysis. Ann Surg Oncol 2014;21 Suppl 3:S443-50. [PMID: 24604581 DOI: 10.1245/s10434-014-3581-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
163 Anton N, Parlog A, Bou About G, Attia MF, Wattenhofer-Donzé M, Jacobs H, Goncalves I, Robinet E, Sorg T, Vandamme TF. Non-invasive quantitative imaging of hepatocellular carcinoma growth in mice by micro-CT using liver-targeted iodinated nano-emulsions. Sci Rep 2017;7:13935. [PMID: 29066853 DOI: 10.1038/s41598-017-14270-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
164 Wong RJ, Kim D, Ahmed A, Singal AK. Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality. Cancer 2020;127:45-55. [PMID: 33103243 DOI: 10.1002/cncr.33211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
165 Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595-608. [PMID: 29404481 DOI: 10.1002/hep4.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
166 Ioannou GN, Tang W, Beste LA, Tincopa MA, Su GL, Van T, Tapper EB, Singal AG, Zhu J, Waljee AK. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. JAMA Netw Open. 2020;3:e2015626. [PMID: 32870314 DOI: 10.1001/jamanetworkopen.2020.15626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
167 Baffy G. Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 63-77. [DOI: 10.1007/978-981-10-8684-7_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
168 Thomas R, Thomas RS, Auerbach SS, Portier CJ. Biological networks for predicting chemical hepatocarcinogenicity using gene expression data from treated mice and relevance across human and rat species. PLoS One 2013;8:e63308. [PMID: 23737943 DOI: 10.1371/journal.pone.0063308] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
169 Prenner S, Kulik L. HCC: Where Does HCV Therapy Play a Role? Curr Hepatology Rep 2016;15:17-25. [DOI: 10.1007/s11901-016-0292-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
170 Fuster D, García-Calvo X, Zuluaga P, Bolao F, Muga R. Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use. World J Gastroenterol 2021; 27(23): 3223-3237 [PMID: 34163107 DOI: 10.3748/wjg.v27.i23.3223] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Goldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman A, Baytarian M, Fox R, Hunt K, Pedrosa M. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology. 2017;65:864-874. [PMID: 27531119 DOI: 10.1002/hep.28765] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
172 Huang ZY, Liang BY, Xiong M, Zhan DQ, Wei S, Wang GP, Chen YF, Chen XP. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol 2012;19:2515-25. [PMID: 22395985 DOI: 10.1245/s10434-012-2269-7] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 7.0] [Reference Citation Analysis]
173 Nazareth S, Leembruggen N, Tuma R, Chen SL, Rao S, Kontorinis N, Cheng W. Nurse-led hepatocellular carcinoma surveillance clinic provides an effective method of monitoring patients with cirrhosis. Int J Nurs Pract 2016;22 Suppl 2:3-11. [PMID: 27476494 DOI: 10.1111/ijn.12472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
174 Winters AC, Sung JC, Wyatt B, Berera D, Schiano TD, Schwartz ME, Perumalswami PV, Branch AD. At diagnosis of hepatocellular carcinoma, African Americans with hepatitis C have better liver function than other patients. Clin Liver Dis (Hoboken) 2018;12:109-12. [PMID: 30416720 DOI: 10.1002/cld.745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
175 Luu S, Hsu C, Silberfein EJ. Demographic and Clinicopathologic Factors of Patients With Hepatocellular Carcinoma in a Safety Net Hospital. J Surg Res 2020;256:374-80. [PMID: 32739621 DOI: 10.1016/j.jss.2020.06.046] [Reference Citation Analysis]
176 Singal AG, Waljee AK, Patel N, Chen EY, Tiro JA, Marrero JA, Yopp AC. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2013;11:1101-8. [PMID: 24029125 DOI: 10.6004/jnccn.2013.0131] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
177 Sanoff HK, Chang Y, Stavas JM, Stürmer T, Lund J. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. J Natl Compr Canc Netw 2015;13:1102-10. [PMID: 26358794 DOI: 10.6004/jnccn.2015.0135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
178 Fortune BE, Umman V, Gilliland T, Emre S. Liver transplantation for hepatocellular carcinoma: a surgical perspective. J Clin Gastroenterol 2013;47 Suppl:S37-42. [PMID: 23632344 DOI: 10.1097/MCG.0b013e318286ff8e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
179 Carr BI, Bag HG, Ince V, Akbulut S, Ersan V, Usta S, Isik B, Ogut Z, Tuncer A, Yilmaz S. A Combination of Blood Lymphocytes and AST Levels Distinguishes Patients with Small Hepatocellular Carcinomas from Non-cancer Patients. J Gastrointest Cancer 2021. [PMID: 34762264 DOI: 10.1007/s12029-021-00740-9] [Reference Citation Analysis]
180 Aby E, Phan J, Truong E, Grotts J, Saab S. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis. Journal of Clinical Gastroenterology 2019;53:142-6. [DOI: 10.1097/mcg.0000000000001075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
181 Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. PLoS One 2015;10:e0138907. [PMID: 26398404 DOI: 10.1371/journal.pone.0138907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
182 Boudreault S, Chen J, Wu KY, Plüddemann A, Heneghan C. Self-management programmes for cirrhosis: A systematic review. J Clin Nurs 2020;29:3625-37. [PMID: 32671877 DOI: 10.1111/jocn.15416] [Reference Citation Analysis]
183 Paranaguá-Vezozzo DC, Ono SK, Alvarado-Mora MV, Farias AQ, Cunha-Silva M, França JI, Alves VA, Sherman M, Carrilho FJ. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort. Ann Hepatol 2014;13:386-93. [PMID: 24927609 [PMID: 24927609 DOI: 10.1016/s1665-2681(19)30845-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
184 Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 2013;38:703-12. [PMID: 23957569 DOI: 10.1111/apt.12450] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 7.1] [Reference Citation Analysis]
185 Rajasekharan C, Ganga V. A rare cause for acute cor pulmonale. Case Rep Gastroenterol 2011;5:330-5. [PMID: 21712949 DOI: 10.1159/000329348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
186 Simmons OL, Feng Y, Parikh ND, Singal AG. Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol 2019;17:766-73. [PMID: 30056183 DOI: 10.1016/j.cgh.2018.07.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
187 Flemming JA, Saxena V, Shen H, Terrault NA, Rongey C. Facility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA. Dig Dis Sci. 2016;61:62-69. [PMID: 26363933 DOI: 10.1007/s10620-015-3865-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
188 Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology 2018;67:1784-96. [DOI: 10.1002/hep.29668] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
189 Salgia R, Singal AG. Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America 2014;98:103-18. [DOI: 10.1016/j.mcna.2013.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
190 Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:779-792. [PMID: 21357378 DOI: 10.1158/1055-9965] [Cited by in F6Publishing: 75] [Reference Citation Analysis]
191 Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist 2016;21:1113-20. [PMID: 27185615 DOI: 10.1634/theoncologist.2015-0478] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
192 Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425-432. [PMID: 23337478 DOI: 10.1038/ajg.2012.449] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
193 Robinson A, Tavakoli H, Cheung R, Liu B, Bhuket T, Wong RJ. Low Rates of Retention Into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening. J Clin Gastroenterol 2019;53:65-70. [PMID: 29629906 DOI: 10.1097/MCG.0000000000001024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
194 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol 2021;12:S361-73. [PMID: 34422400 DOI: 10.21037/jgo.2020.02.08] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
195 Thein HH, Isaranuwatchai W, Campitelli MA, Feld JJ, Yoshida E, Sherman M, Hoch JS, Peacock S, Krahn MD, Earle CC. Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology 2013;58:1375-84. [PMID: 23300063 DOI: 10.1002/hep.26231] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 4.9] [Reference Citation Analysis]
196 Hesketh RL, Zhu AX, Oklu R. Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol 2015;38:431-6. [PMID: 25238287 DOI: 10.1097/COC.0000000000000123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
197 Chen VL, Le AK, Kim NG, Kim LH, Nguyen NH, Nguyen PP, Zhao C, Nguyen MH. Effects of Cirrhosis on Short-term and Long-term Survival of Patients With Hepatitis B-related Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2016;14:887-895.e1. [PMID: 26820401 DOI: 10.1016/j.cgh.2015.12.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
198 Zhao C, Nguyen MH. Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life Practice. J Clin Gastroenterol. 2016;50:120-133. [PMID: 26583266 DOI: 10.1097/mcg.0000000000000446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
199 Del Poggio P, Olmi S, Ciccarese F, Mazzoleni M, Jazzetti M, Jamoletti C, Mattiello M, Del Poggio A, Portugali V, Stroffolini T. A training program for primary care physicians improves the effectiveness of ultrasound surveillance of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2015;27:1103-8. [PMID: 26049705 DOI: 10.1097/MEG.0000000000000404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
200 Ahmed Mohammed HA, Yang JD, Giama NH, Choi J, Ali HM, Mara KC, Harmsen WS, Wiesner RH, Leise MD, Therneau TM, Roberts LR. Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. Liver Cancer. 2017;6:126-136. [PMID: 28275579 DOI: 10.1159/000450833] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
201 van Meer S, de Man RA, Coenraad MJ, Sprengers D, van Nieuwkerk KM, Klümpen HJ, Jansen PL, IJzermans JN, van Oijen MG, Siersema PD. Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands. J Hepatol. 2015;63:1156-1163. [PMID: 26100498 DOI: 10.1016/j.jhep.2015.06.012] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 10.9] [Reference Citation Analysis]
202 Persson EC, Quraishi SM, Welzel TM, Carreon JD, Gridley G, Graubard BI, McGlynn KA. Risk of liver cancer among US male veterans with cirrhosis, 1969-1996. Br J Cancer 2012;107:195-200. [PMID: 22588556 DOI: 10.1038/bjc.2012.193] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
203 Aby ES, Winters AC, Lin J, Bui A, Kawamoto J, Goetz MB, Bhattacharya D, Pisegna JR, May FP, Patel AA, Benhammou JN. A Telephone and Mail Outreach Program Successfully Increases Uptake of Hepatocellular Carcinoma Surveillance. Hepatol Commun 2020;4:825-33. [PMID: 32490319 DOI: 10.1002/hep4.1511] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Chen J, Wu M, Gong J, Liu Z, He G, Zhu H, Li Z, Hu B. Influence of Alanine Transaminase Levels on Alpha-Fetoprotein for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Infection. Biomed Res Int 2020;2020:2043715. [PMID: 33490235 DOI: 10.1155/2020/2043715] [Reference Citation Analysis]
205 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 3.9] [Reference Citation Analysis]
206 Wang J, Ha J, Lopez A, Bhuket T, Liu B, Wong RJ. Medicaid and Uninsured Hepatocellular Carcinoma Patients Have More Advanced Tumor Stage and Are Less Likely to Receive Treatment. J Clin Gastroenterol 2018;52:437-43. [PMID: 28723861 DOI: 10.1097/MCG.0000000000000859] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
207 Trinchet J, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Goria O, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Blanc J, Abergel A, Serfaty L, Mallat A, Grangé J, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S; and the ANRS CO12 CirVir Group. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort): HEPATOLOGY, Vol. XX, No. X, 2015 TRINCHET ET AL. Hepatology 2015;62:737-50. [DOI: 10.1002/hep.27743] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 8.7] [Reference Citation Analysis]
208 Robinson A, Ohri A, Liu B, Bhuket T, Wong RJ. One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation. World J Hepatol 2018; 10(12): 956-965 [PMID: 30631400 DOI: 10.4254/wjh.v10.i12.956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
209 Durand-Zaleski I, Bulsei J, Seror O, Nahon P. Reply. Hepatology 2017;66:300-1. [PMID: 28380685 DOI: 10.1002/hep.29193] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
210 Goossens N, Nakagawa S, Hoshida Y. Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol 2015; 21(36): 10262-10273 [PMID: 26420954 DOI: 10.3748/wjg.v21.i36.10262] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
211 Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, Navascués CA, Sotorríos NG, Martínez M, Rodrigo L, Rodríguez M. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol. 2013;11:95-101. [PMID: 22982095 DOI: 10.1016/j.cgh.2012.09.007] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 8.9] [Reference Citation Analysis]
212 Rodriguez Villalvazo Y, McDanel JS, Beste LA, Sanchez AJ, Vaughan-Sarrazin M, Katz DA. Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis. Health Serv Res 2020;55:103-12. [PMID: 31763691 DOI: 10.1111/1475-6773.13241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
213 Wu EM, Wong LL, Hernandez BY, Ji JF, Jia W, Kwee SA, Kalathil S. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res 2018;4:66. [PMID: 30687780 DOI: 10.20517/2394-5079.2018.87] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
214 Peyton A, Martin P. Primary Care of Patients with Cirrhosis – Current and Future Challenges. Curr Hepatology Rep 2014;13:1-7. [DOI: 10.1007/s11901-014-0219-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
215 Goldberg DS, Valderrama A, Kamalakar R, Sansgiry SS, Babajanyan S, Lewis JD. Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance. J Clin Gastroenterol 2016;50:258-65. [PMID: 26352107 DOI: 10.1097/MCG.0000000000000411] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
216 Rongey C, Shen H, Hamilton N, Backus LI, Asch SM, Knight S, Jhaveri R. Impact of Rural Residence and Health System Structure on Quality of Liver Care. PLoS ONE 2013;8:e84826. [DOI: 10.1371/journal.pone.0084826] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
217 Nusbaum JD, Smirniotopoulos J, Wright HC, Dash C, Parpia T, Shechtel J, Chang Y, Loffredo C, Shetty K. The Effect of Hepatocellular Carcinoma Surveillance in an Urban Population With Liver Cirrhosis. J Clin Gastroenterol. 2015;Epub ahead of print. [PMID: 25751372 DOI: 10.1097/mcg.0000000000000306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
218 Ajayi F, Jan J, Singal AG, Rich NE. Racial and Sex Disparities in Hepatocellular Carcinoma in the USA. Curr Hepatol Rep 2020;19:462-9. [PMID: 33828937 DOI: 10.1007/s11901-020-00554-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
219 Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014;12:375-82. [PMID: 24616543 DOI: 10.6004/jnccn.2014.0039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
220 El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011;4:5-10. [PMID: 21317990 DOI: 10.1177/1756283x10385964] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
221 Carr BI, Bag HG, Ince V, Ogut Z, Tuncer A, Akbulut S, Ersan V, Usta S, Isik B, Yilmaz S. A simple 2-parameter blood test alert for the presence of small hepatocellular carcinomas. Clin Pract (Lond) 2021;18:1804-9. [PMID: 34966540] [Reference Citation Analysis]
222 El-Serag HB, Kanwal F. α-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013;11:441-443. [PMID: 23376321 DOI: 10.1016/j.cgh.2012.12.046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
223 Mancebo A, González-Diéguez ML, Navascués CA, Cadahía V, Varela M, Pérez R, Rodrigo L, Rodríguez M. Adherence to a Semiannual Surveillance Program for Hepatocellular Carcinoma in Patients With Liver Cirrhosis. J Clin Gastroenterol 2017;51:557-63. [PMID: 27775957 DOI: 10.1097/MCG.0000000000000734] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
224 Masuoka HC, Rosen CB. Liver Transplantation for Hepatocellular Carcinoma: Expanding Frontiers and Building Bridges. Clinics in Liver Disease 2011;15:385-93. [DOI: 10.1016/j.cld.2011.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
225 Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D; ANRS CO13 Hepavih study group., ANRS CO12 Cirvir study group. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol 2012;36:214-21. [PMID: 22189509 DOI: 10.1016/j.clinre.2011.11.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
226 Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS, Marrero JA. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793-799. [PMID: 22374994 DOI: 10.1158/1055-9965.epi-11-1005] [Cited by in Crossref: 157] [Cited by in F6Publishing: 92] [Article Influence: 15.7] [Reference Citation Analysis]
227 Cooper GS. Should We Abandon Current Hepatocellular Carcinoma Screening Practices? Gastroenterology 2018;155:972-4. [DOI: 10.1053/j.gastro.2018.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
228 Saberifiroozi M. Improving Quality of Care in Patients with Liver Cirrhosis. Middle East J Dig Dis 2017;9:189-200. [PMID: 29255576 DOI: 10.15171/mejdd.2017.73] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
229 Khalil A, Elsheashaey A, Abdelsameea E, Obada M, Bayomy F.f. M, El-said H. Value of Bile Acids in Diagnosing Hepatitis C Virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma. Br J Biomed Sci 2022;79:10191. [DOI: 10.3389/bjbs.2021.10191] [Reference Citation Analysis]
230 Palmer LB, Kappelman MD, Sandler RS, Hayashi PH. Surveillance for hepatocellular carcinoma in a Medicaid cirrhotic population. J Clin Gastroenterol. 2013;47:713-718. [PMID: 23442840 DOI: 10.1097/mcg.0b013e318286fd97] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
231 Li R, Cai P, Ma KS, Ding SY, Guo DY, Yan XC. Dynamic enhancement patterns of intrahepatic cholangiocarcinoma in cirrhosis on contrast-enhanced computed tomography: risk of misdiagnosis as hepatocellular carcinoma. Sci Rep. 2016;6:26772. [PMID: 27226026 DOI: 10.1038/srep26772] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
232 Fitian AI, Nelson DR, Liu C, Xu Y, Ararat M, Cabrera R. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver Int 2014;34:1428-44. [PMID: 24661807 DOI: 10.1111/liv.12541] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
233 Zu QQ, Liu S, Zhou CG, Yang ZQ, Xia JG, Zhao LB, Shi HB. Chemoembolization of recurrent hepatoma after curative resection: prognostic factors. AJR Am J Roentgenol 2015;204:1322-8. [PMID: 26001244 DOI: 10.2214/AJR.14.13343] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
234 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
235 Robinson A, Tavakoli H, Liu B, Bhuket T, Wong RJ. Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening. Hepatol Commun 2018;2:1147-55. [PMID: 30202827 DOI: 10.1002/hep4.1236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
236 Wigg AJ, McCormick R, Wundke R, Woodman RJ. Efficacy of a chronic disease management model for patients with chronic liver failure. Clin Gastroenterol Hepatol. 2013;11:850-858.e1-4. [PMID: 23375997 DOI: 10.1016/j.cgh.2013.01.014] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
237 McMahon B, Block J, Block T, Cohen C, Evans AA, Hosangadi A, London WT, Sherman M; 2015 Princeton HCC Workshop participants. Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care. J Natl Cancer Inst 2016;108:djv359. [PMID: 26626106 DOI: 10.1093/jnci/djv359] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
238 Park SH, Heo NY, Park JH, Kim TO, Yang SY, Kim HK, Moon YS, Kim CH, Suk KT, Kim DJ, Lee HY. Hepatocellular carcinoma screening in a hepatitis B virus-infected Korean population. Dig Dis Sci 2012;57:3258-64. [PMID: 22729598 DOI: 10.1007/s10620-012-2281-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
239 Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci 2020;65:3456-62. [PMID: 32860090 DOI: 10.1007/s10620-020-06550-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
240 Patwardhan V, Paul S, Corey KE, Mazhar SM, Richter JM, Thiim M, Chung RT. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci. 2011;56:3316-3322. [PMID: 21805170 DOI: 10.1007/s10620-011-1836-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
241 Costentin C, Ganne-Carrié N, Rousseau B, Gérolami R, Barbare JC. [Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017]. Bull Cancer 2017;104:752-61. [PMID: 28751065 DOI: 10.1016/j.bulcan.2017.06.008] [Reference Citation Analysis]
242 Chen H, Zhang Y, Li S, Li N, Chen Y, Zhang B, Qu C, Ding H, Huang J, Dai M. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res 2018;10:1947-58. [PMID: 30022853 DOI: 10.2147/CMAR.S167036] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
243 Zhao C, Xing F, Yeo YH, Jin M, Le R, Le M, Jin M, Henry L, Cheung R, Nguyen MH. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:406-19. [PMID: 31490419 DOI: 10.1097/MEG.0000000000001523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
244 Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 2019;71:523-33. [PMID: 31145929 DOI: 10.1016/j.jhep.2019.05.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
245 Mangia A, Bellini D, Cillo U, Laghi A, Pelle G, Valori VM, Caturelli E. Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterol 2020;20:251. [PMID: 32746786 DOI: 10.1186/s12876-020-01391-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
246 Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015;121:2874-82. [PMID: 26079399 DOI: 10.1002/cncr.29528] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
247 Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology 2012;56:397-405. [DOI: 10.1016/j.jhep.2011.05.026] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
248 Barman PM, Sharma P, Krishnamurthy V, Willatt J, McCurdy H, Moseley RH, Su GL. Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Dig Dis Sci. 2014;59:2821-2825. [PMID: 24973040 DOI: 10.1007/s10620-014-3247-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
249 Chung JW, Kim BH, Lee CS, Kim GH, Sohn HR, Min BY, Song JC, Park HK, Jang ES, Yoon H, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Lee J, Ahn S, Kim JW. Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS One 2016;11:e0168189. [PMID: 27997559 DOI: 10.1371/journal.pone.0168189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
250 Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA. LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2016;43:385-399. [PMID: 26662476 DOI: 10.1111/apt.13485] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
251 Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stål P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int 2015;35:1862-71. [PMID: 25524812 DOI: 10.1111/liv.12764] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
252 Singal AG, Tiro JA, Murphy CC, Blackwell JM, Kramer JR, Khan A, Liu Y, Zhang S, Phillips JL, Hernaez R. Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:987-995.e1. [PMID: 32629122 DOI: 10.1016/j.cgh.2020.06.049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
253 Fazeli S, Covarrubias Y, Bassirian S, Cuevas J, Fowler K, Vodkin I, Kono Y, Marks R, Loomba R, Taouli B, Sirlin C, Carlos R. Eliciting Patient Preferences for Hepatocellular Carcinoma Screening: A Choice-Based Conjoint Analysis. Journal of the American College of Radiology 2022. [DOI: 10.1016/j.jacr.2022.01.015] [Reference Citation Analysis]
254 Singal AG, Dharia TD, Malet PF, Alqahtani S, Zhang S, Cuthbert JA. Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open 2013;3:e003231. [PMID: 24002983 DOI: 10.1136/bmjopen-2013-003231] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
255 Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma 2019;6:131-41. [PMID: 31440486 DOI: 10.2147/JHC.S159269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
256 Robinson A, Tavakoli H, Liu B, Bhuket T, Cheung R, Wong RJ. African-Americans with Cirrhosis Are Less Likely to Receive Endoscopic Variceal Screening Within One Year of Cirrhosis Diagnosis. J Racial Ethn Health Disparities 2018;5:860-6. [PMID: 29052175 DOI: 10.1007/s40615-017-0432-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
257 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19(47): 8808-8821 [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
258 Tayob N, Richardson P, White DL, Yu X, Davila JA, Kanwal F, Feng Z, El-Serag HB. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 2018;18:1. [PMID: 29301497 DOI: 10.1186/s12874-017-0458-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
259 Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;12:1347-57. [DOI: 10.1586/era.12.113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
260 Iavarone M, Viganò M, Piazza N, Occhipinti V, Sangiovanni A, Maggioni M, D'Ambrosio G, Forzenigo LV, Motta F, Lampertico P, Rumi MG, Colombo M. Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. Ann Hepatol 2019;18:318-24. [PMID: 31036496 DOI: 10.1016/j.aohep.2018.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]